Molecular Biological Markers for Toxicology and Risk Assessment
Description:
Molecular Biological Markers for Toxicology and Risk Assessment provides an introduction to the exciting field of biomarkers and their use in toxicology and risk assessment. In recent years, new classes of molecular biomarkers capable of detecting early manifestations of ongoing chemical-induced cell injury and cell death have been developed as a result of advances in analytical chemistry, molecular biology, and computational modeling. The interplay between these emergent tools of science has resulted in new insights into initial mechanisms of chemical-induced toxicity and carcinogenicity.
Molecular Biological Markers for Toxicology and Risk Assessment guides the reader through a broad range of molecular biological markers, including the "omic" biomarkers, and provides an examination of the various elements in the evolution of these modern tools. It then explores possible ways in which these markers may be applied to advance the field of chemical risk assessment. Since molecular biomarkers and related technologies are inherently complex, the book concludes with a section on risk communication in order that readers may appreciate both the strengths and limitations of molecular biological marker approaches to risk assessment practice.
Best prices to buy, sell, or rent ISBN 9780128095898
Frequently Asked Questions about Molecular Biological Markers for Toxicology and Risk Assessment
The price for the book starts from $63.99 on Amazon and is available from 11 sellers at the moment.
If you’re interested in selling back the Molecular Biological Markers for Toxicology and Risk Assessment book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Molecular Biological Markers for Toxicology and Risk Assessment book, the best buyback offer comes from and is $ for the book in good condition.
Not enough insights yet.
Not enough insights yet.